The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Official Title: A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Study ID: NCT05568225
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Miami Hospital and Clinics, Miami, Florida, United States
Ocala Oncology, Ocala, Florida, United States
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Maimonides Medical Center, Brooklyn, New York, United States
NYU Langone Health, New York, New York, United States
Columbia University Irving Medical Center, New York, New York, United States
Baptist Clinical Research Institute, Memphis, Tennessee, United States
University of British Columbia - St. Paul's Hospital, Vancouver, British Columbia, Canada
Nice University Hospital - Hôpital de l'Archet, Route De Saint-Antoine, Nice, France
Hôpital Avicenne, Bobigny, , France
CHU de Nantes - Hôtel Dieu, Nantes, , France
Hopital Saint Louis, Paris, , France
Universitoetsklinikum Heidelberg, Heidelberg, , Germany
Universitaetsklinikum Muenster, Münster, , Germany
Universitoetsklinikum Halle (Saale), Münster, , Germany
Name: Clinical Transparency (dept. 2834), MD
Affiliation: Novo Nordisk A/S
Role: STUDY_DIRECTOR